Clinical Trials Directory

Trials / Completed

CompletedNCT02840669

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Adverum Biotechnologies, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Friedreich's ataxia (FA) is an autosomal recessive disease with an incidence of 1/50,000 in the Caucasian population. The main manifestations of FA are progressive sensory and cerebellar ataxia and cardiomyopathy (CM). It is the most common form of inherited ataxia. A severe CM affects \~60% of FA patients, mostly young adults, and leads to cardiac failure then death. Currently, no therapy can change the course of this severe cardiomyopathy. This study is designed to characterize the cardiac manifestations of FA using cardiac magnetic resonance (CMR), echocardiography, serum cardiac biomarkers and evaluation of fatigue severity, in the context of the neurological disease.

Conditions

Interventions

TypeNameDescription
PROCEDURECardiac magnetic resonance imaging (CMR)
PROCEDUREExercise-stress test
PROCEDUREEchocardiography (ECHO)
PROCEDURECardiac-related blood studies

Timeline

Start date
2016-07-01
Primary completion
2018-06-01
Completion
2018-09-01
First posted
2016-07-21
Last updated
2018-12-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02840669. Inclusion in this directory is not an endorsement.